文献速递泌尿系感染

标准与扩展尿培养诊断女性尿路感染的随机临床试验

A Randomized Clinical Trial of Standard versus Expanded Cultures to Diagnose Urinary Tract Infections in Women.
PubMed 文献 · J Urol · 2021-06-29

本研究将出现尿路感染症状的女性随机按2:1分配至标准尿培养(SUC)或扩展定量尿培养(EQUC)指导治疗,比较7-10天症状缓解率。结果显示两组总体症状缓解率相似(64% vs 69%,p=0.46),但EQUC组UTISA评分改善更显著(p=0.04),非大肠埃希菌亚组中EQUC组症状缓解有增多趋势(21%,p=0.08)。

要点

  • SUC与EQUC指导治疗在总体症状缓解率上无显著差异(64% vs 69%,p=0.46)。
  • EQUC组UTISA评分较基线改善优于SUC组(p=0.04)。
  • 非大肠埃希菌亚组中EQUC组症状缓解有增多趋势(21%,p=0.08),但样本量有限。

核心结论

  • 在因尿路感染症状接受治疗的整体女性人群中,基于SUC或EQUC指导治疗的7-10天症状缓解率相似。
  • 非大肠埃希菌尿路病原体女性中EQUC的效用尚不能得出结论,但检测到的趋势提示该研究不足的临床亚组值得进一步研究。

研究设计与样本

  • 随机临床试验,女性≥18岁且对「您是否感觉有尿路感染?」回答「是」,同意尿道导尿和随访。
  • 培养方法按2:1随机分配至标准尿培养(SUC)或扩展定量尿培养(EQUC),培养阳性者处方抗生素。
  • 主要结局为入组后7-10天所有参与者的尿路感染症状缓解,无论是否治疗。

主要发现

  • SUC组和EQUC组分别有63%和74%培养阳性(p=0.10)。
  • 培养阳性参与者中97%接受了抗生素。
  • 225名参与者中215名(SUC 143 [95%],EQUC 72 [97%])提供了主要结局数据。
  • 主要结局评估时,SUC组和EQUC组分别有64%和69%报告尿路感染症状缓解(p=0.46)。
  • EQUC组UTISA评分较基线改善优于SUC组(p=0.04);以非大肠埃希菌为主的女性亚组(76例)中EQUC组症状缓解有增多趋势(21%,p=0.08)。

临床怎么用

  • 对于因尿路感染症状就诊的女性,基于SUC指导抗生素治疗在总体症状缓解上与EQUC相似。
  • EQUC可能改善UTISA评分,但现有样本量不足以支持在非大肠埃希菌感染女性中常规使用EQUC。

局限性

  • 样本量限制了对非大肠埃希菌尿路病原体女性中EQUC效用的结论。
  • 非大肠埃希菌亚组分析仅为趋势性发现(p=0.08),需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We compared urinary tract infection (UTI) symptom resolution rates at 7-10 days in symptomatic women randomized to treatment based on standard urine culture (SUC) versus expanded quantitative urine culture (EQUC) results. MATERIALS AND METHODS: Women ≥18 years old who responded "yes" to "do you feel you have a UTI?" agreed to urethral catheterization and followup. Symptoms were assessed using the validated UTI Symptom Assessment (UTISA) questionnaire. Culture method was randomized 2:1 (SUC:EQUC); antibiotics were prescribed to women with positive cultures. The primary outcome, UTI symptom resolution, was determined 7-10 days following enrollment on all participants regardless of treatment. RESULTS: Demographic data were similar between groups. Of the SUC and EQUC groups 63% and 74% had positive cultures (p=0.10), respectively. Of participants with positive cultures 97% received antibiotics. Primary outcome data were provided by 215 of 225 participants (SUC 143 [95%], EQUC 72 [97%]). At the primary outcome assessment, 64% and 69% in the SUC and EQUC groups, respectively, reported UTI symptom resolution (p=0.46); UTISA scores improved from baseline in the EQUC arm compared to the SUC arm (p=0.04). In the subset of women predominated by non-Escherichia coli (76), there was a trend toward more symptom resolution in the EQUC arm (21%, p=0.08). CONCLUSIONS: Symptom resolution was similar for the overall population (E. coli and non-E. coli) of women treated for UTI symptoms based on SUC or EQUC. Although the sample size limits conclusions regarding the utility of EQUC in women with non-E. coli uropathogens, the detected trend indicates that this understudied clinical subset warrants further study.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Barnes HC, Wolff B, Abdul-Rahim O, et al. A Randomized Clinical Trial of Standard versus Expanded Cultures to Diagnose Urinary Tract Infections in Women. J Urol. 2021. PMID: 34184930. doi:10.1097/JU.0000000000001949

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。